NEW YORK ( TheStreet) -- CHANGE IN RATINGSCubist Pharmaceuticals ( CBST) rated new Buy at Goldman. Stock also placed on the Conviction List. $54 price target. CXA will likely be the company's next big growth driver. CVS Caremark ( CVS) upgraded at BMO from Market Perform to Outperform, BMO Capital said. $53 price target. Company should see improved margins and earnings power in the coming quarters. Dril-Quip ( DRQ) downgraded at BofA/Merrill from Buy to Underperform, Bank of America/Merrill Lynch said. Valuation call, based on a $79 price target. FirstEnergy ( FE) downgraded at UBS to Neutral from Buy, UBS said. $49 price target. Standing aside on opaque outlook. First Energy downgraded at BMO from Outperform to Market Perform, BMO Capital said. $48 price target. Management has limited earnings visibility. Fossil ( FOSL) downgraded at Citigroup to Neutral from Buy, Citigroup said. $100 price target. Valuation call after rally on quarterly results. Groupon ( GRPN) downgraded at Sterne Agee from Buy to Neutral, Sterne Agee said. Estimates also cut, as growth appears to be slowing. Halliburton ( HAL) upgraded to buy at TheStreet Ratings. Jive Software ( JIVE) downgraded at Citigroup to Neutral from Buy, Citigroup said. $21 price target. Thesis not playing out as fast as we'd hoped. Jack Henry ( JKHY) upgraded at Wells from Market Perform to Outperform, Wells Fargo said. Company has a strong balance sheet and the spending environment is improving. MGE Energy ( MGEE) upgraded at DA Davidson from Underperform to Neutral, DA Davidson said. Valuation call, based on a $48.50 price target. MGM ( MGM) downgraded to sell at TheStreet Ratings. VeriFone ( PAY) downgraded at UBS to Neutral from Buy, UBS said. $41 price target. Catalysts played out. Par Pharmaceutical ( PRX) downgrade at UBS to Neutral from Buy, UBS said. $58 price target. Valuation call given current TPG offer price. Rackspace ( RAX) upgraded at Pacific Crest to Outperform, Pacific Crest said. $62 price target. Company is realizing higher margins. Sapient ( SAPE) downgraded at Wells from Outperform to Market Perform, Wells Fargo said. Company is seeing slower growth in its Nitro segment. Vectren ( VVC) rated new Buy at Brean. $36 price target. Company has a solid yield and can deliver consistent growth over the long term.